Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer

Overview of attention for article published in PLOS ONE, March 2013

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (88th percentile)
High Attention Score compared to outputs of the same age and source (85th percentile)

Mentioned by

news: 1 news outlet
twitter: 1 X user

f1000: 1 research highlight platform

Citations

dimensions_citation: 185 Dimensions

Readers on

mendeley: 79 Mendeley

Summary News X Research highlights Dimensions citations

So far, Altmetric has seen 3 reviews on 1 research highlight platform.

Recommended in Faculty Opinions

01 Jul 2013

This research output was recommended by a member of Faculty Opinions.

Recommended in Faculty Opinions

13 May 2013

This research output was recommended by a member of Faculty Opinions.

Recommended in Faculty Opinions

16 Apr 2013

This research output was recommended by a member of Faculty Opinions.

This page shows the most recent research highlights that mention this research output.

Click here to find out how to access more activity.